+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Trends in the development of new antidepressants. Is there a light at the end of the tunnel?



Trends in the development of new antidepressants. Is there a light at the end of the tunnel?



Current Medicinal Chemistry 11(7): 925-943



Since the introduction of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) in mid-1950's, treatment of depression has been dominated by monoamine hypotheses. The well-established clinical efficacy of TCAs and MAOIs is due, at least in part, to the enhancement of noradrenergic or serotonergic mechanisms, or to both. Unfortunately, their very broad mechanisms of action also include many unwanted effects related to their potent activity on cholinergic, adrenergic and histaminergic receptors. The introduction of selective serotonin reuptake inhibitors (SSRIs) over twenty years ago had been the next major step in the evolution of antidepressants to develop drugs as effective as the TCAs but of higher safety and tolerability profile. During the past two decades SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) gained incredible popularity and have become the most widely prescribed medication in the psychiatric practice. The evolution of antidepressants continued resulting in introduction of selective and reversible monoamine oxidase inhibitors (eg. moclobemid), selective noradrenaline (eg. reboxetine), dual noradrenaline and serotonin reuptake inhibitors (milnacipram, venlafaxin, duloxetin) and drugs with distinct neurochemical profiles such as mirtazapine, nefazadone and tianeptine. Different novel serotonin receptor ligands have also been intensively investigated. In spite of the remarkable structural diversity, most currently introduced antidepressants are 'monoamine based'. Furthermore, these newer agents are neither more efficacious nor rapid acting than their predecessors and approximately 30% of the population do not respond to current therapies. By the turn of the new millennium, we are all witnessing a result of innovative developmental strategies based on the better understanding of pathophysiology of depressive disorder. Several truly novel concepts have emerged suggesting that the modulation of neuropeptide (substance P, corticotrophin-releasing factor, neuropeptide Y, vasopressin V1b, melanin-concentrating hormone-1), N-methyl-D-aspartate, nicotinic acetylcholine, dopaminergic, glucocorticoid, delta-opioid, cannabinoid and cytokine receptors, gamma-amino butyric acid (GABA) and intracellular messenger systems, transcription, neuroprotective and neurogenic factors, may provide an entirely new set of potential therapeutic targets, giving hope that further major advances might be anticipated in the treatment of depressive disorder soon. The goal of this review is to give a brief overview of the major advances from monoamine-based treatment strategies, and particularly focus on the new emerging approaches in the treatment of depression.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035985579

Download citation: RISBibTeXText

PMID: 15078174


Related references

Studying nerve conduction velocity and latency of accessory nerve motor potential in normal persons. Electromyography and Clinical Neurophysiology 44(1): 11-14, 2004

Sickle Cell Anemia and Antisickling Agents Then and Now. Current Medicinal Chemistry 8(2): 79-88, 2001

Current trends in the abundance of the benthic amphipod Diporeia in southern Lake Michigan. IAGLR Conference Program and Abstracts 45: 91-92, 2002

Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening. Obstetrics and Gynecology 81(5 ): 675-678, 1993

Antidepressants, benzodiazepines, and convulsions. Biological Psychiatry 18(4): 517, 1983

Heave in black shales. Pages 424-426:, 1978

Light at the end of the tunnel. Journal of Indian Society of Periodontology 17(5): 564, 2013

Barlow's Mitral Valve Disease: A Comparison of Neochordal (Loop) and Edge-To-Edge (Alfieri) Minimally Invasive Repair Techniques. Annals of Thoracic Surgery 100(6): 2127-33; Discussion 2133-5, 2015

Chagas disease: national survey of seroprevalence in children under five years of age conducted in 2008. Memorias do Instituto Oswaldo Cruz 112(5): 348-353, 2017

Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain. Journal of Nuclear Medicine 55(9): 1513-1518, 2014

Light intensity determines temporal niche switching of behavioral activity in deep-water Nephrops norvegicus (Crustacea: Decapoda). Journal of Biological Rhythms 25(4): 277-287, 2010

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. Viruses 2(8): 1564-1570, 2010

Symposium 5 resistant depression and atypical depression: possible aetiologies and treatments chairman: R. Daly (ireland). Journal of Psychopharmacology 2(3-4): 176-178, 1988

On-road driving performance by persons with hemianopia and quadrantanopia. Investigative Ophthalmology and Visual Science 50(2): 577-585, 2009

Tunnel preps: tooth strength preservation. Dentistry Today 33(4): 102-103, 2014